ImaginAb
PrivateLast Round
Series C
Extension
Sep 14, 2023
Total Funding Raised
$57.8M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ImaginAb operates in Healthcare & Life Sciences and is based in Inglewood, California. Its latest recorded funding round was a Series C Extension round in September 2023.
ImaginAb is a biotechnology company that develops radiopharmaceutical imaging agents and therapies, including its proprietary CD8 ImmunoPET technology for cancer immunotherapy monitoring.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Imaging, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImaginAb Comparables
Compare ImaginAb with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CellSight Technologies | 86% | |
| Suzhou SmartNuclide Biopharmaceutical Co., Ltd. | 76% | |
| Bracco S.p.A. | 74% |
For institutional investors. Book with your work email.
ImaginAb Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Sep 14, 2023 | ||||
| Series C Extension | Mar 14, 2023 | ||||
| Series C | Jun 3, 2021 | ||||
| Series B Extension | Oct 9, 2017 | ||||
| Series B | May 8, 2014 | ||||
Series A | Mar 26, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ImaginAb Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Norgine Ventures | Series C |
| Momentum Biosciences | Series A |
| Parker Institute for Cancer Immunotherapy | Series B Extension |
| Innoviva | Series C Extension |
| Cycad Group | Series A, Series B Extension, Series B, Series C |
| The Raptor Group | Series B Extension, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 43% MoM, reaching 2.4K.
- Jun 3, 2021
$13M round led by Adage Capital Management and Cycad Group.
For institutional investors. Book with your work email.
ImaginAb Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImaginAb's valuation, stock price, and market status.
Is ImaginAb a public or private company?
ImaginAb is a private company.
What is the current stock price of ImaginAb?
ImaginAb is a private company, so its shares have no public market price. Caplight tracks ImaginAb's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImaginAb worth (valuation)?
Valuation information for ImaginAb is not publicly available.
Can I buy ImaginAb stock?
ImaginAb shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImaginAb's last funding round?
ImaginAb's most recent funding round was Series C Extension on September 14, 2023.
Who are the main investors in ImaginAb?
Key investors in ImaginAb include Cycad Group, Adage Capital Management, Mérieux Equity Partners.
Will ImaginAb IPO soon?
No public IPO plans have been announced for ImaginAb.
How can I track ImaginAb secondary market activity?
Caplight tracks bids, offers, and trades in ImaginAb's shares on secondary markets.